Potential impact of microarray diagnosis of t cell-mediated rejection in kidney transplants: The INTERCOM study

American Journal of Transplantation

Volumn 13, Issue 9, 2013, Pages 2352-2363

  Halloran, P F ^a,b   Pereira, A B ^a,c,d   Chang, J ^a   Matas, A ^e   Picton, M ^f   De Freitas, D ^f   Bromberg, J ^g   Seron D ^h   Sellares J ^h   Einecke, G ⁱ   Reeve, J ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Federal University of Minas Gerais ^*  (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e UNIVERSITY OF MINNESOTA   (United States)

^f MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Classifier; kidney transplant; microarrays; molecular diagnostics; T cell mediated rejection

Indexed keywords

ADULT; ARTICLE; ATROPHY; CAPILLARITIS; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA VIRUS INFECTION; FIBROSING ALVEOLITIS; GLOMERULITIS; GRAFT FAILURE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HYALINE DEGENERATION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY INFECTION; MAJOR CLINICAL STUDY; NEPHRITIS; OBSERVATIONAL STUDY; POLYOMA VIRUS; POLYOMA VIRUS INFECTION; PRIORITY JOURNAL; SCAR FORMATION; SCORING SYSTEM; T CELL MEDIATED KIDNEY GRAFT REJECTION; TISSUE MICROARRAY;

CLASSIFIER; KIDNEY TRANSPLANT; MICROARRAYS; MOLECULAR DIAGNOSTICS; T CELL-MEDIATED REJECTION;

ANTIBODIES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MOLECULAR DIAGNOSTIC TECHNIQUES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TUMOR VIRUS INFECTIONS;

EID: 84883452203     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12387     Document Type: Article

References (41)

1. Halloran PF., T cell mediated rejection of kidney transplants: A personal viewpoint. Am J Transplant 2010; 10: 1126-1134.
2. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
3. Mengel M, Sis B, Halloran PF., SWOT analysis of Banff: Strengths, weaknesses, opportunities, and threats of the international Banff consensus process and classification system for renal allograft pathology. Am J Transplant 2007; 7: 2221-2226.
4. Racusen LC, Solez K., Nephrotoxic tubular and interstitial lesions: Morphology and classification. Toxicol Pathol 1986; 14: 45-57.
5. Racusen L, Kashgarian M., Ischemic and toxic acute tubular injury and other ischemic renal injury. In:, Jennette JC, Olson JL, Schwartz MM, Silva FG, eds. Heptinstall's pathology of the kidney, 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2007, pp. 1139-1198.
6. Ivanyi B, Marcussen N, Olsen S., Tubulitis in primary vascular and glomerular renal disease. Pathol Res Pract 1995; 191: 1245-1257.
7. Ferrario F, Vanzati A, Pagni F., Pathology of ANCA-associated vasculitis. Clin Exp Nephrol 2012; 1-7.
8. Kanzaki G, Tsuboi N, Yokoo T, Miyazaki Y, Utsunomiya Y, Hosoya T., Diffuse tubulointerstitial nephritis associated with ANCA-negative pauci-immune glomerulonephritis. Clin Exp Nephrol 2012; 16: 480-484.
9. Berden AE, Jones RB, Erasmus DD, et al. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 2012; 23: 313-321.
10. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
11. de Freitas DG, Sellares J, Mengel M, et al. The nature of biopsies with "Borderline Rejection" and prospects for eliminating this category. Am J Transplant 2012; 12: 191-201.
12. Furness PN, Taub N, Assmann KJ, et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol 2003; 27: 805-810.
13. Furness PN, Taub N., International variation in the interpretation of renal transplant biopsies: Report of the CERTPAP Project. Kidney Int 2001; 60: 1998-2012.
14. Reeve J, Sellares J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant 2013; 13: 645-655.
15. Hirsch HH, Randhawa P., BK polyomavirus in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 4): 179-188.
16. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2010; 58: 1612-1619.
17. Strehlau J, Pavlakis M, Lipman M, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997; 94: 695-700.
18. Sharma VK, Bologa RM, Li BG, et al. Molecular executors of cell death differential intrarenal expression of Fas ligand, Fas, granzyme B and perforin during acute and/or chronic rejection of human renal allografts. Transplant 1996; 62: 1860-1866.
19. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125-138.
20. Flechner SM, Kurian SM, Head SR, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004; 4: 1475-1489.
21. Saint-Mezard P, Berthier CC, Zhang H, et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transpl Int 2009; 22: 293-302.
22. Mengel M, Sis B, Haas M, et al. Banff 2011 meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
23. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
24. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013; 13: 971-983.
25. Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7: 2712-2722.
26. Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: A comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9: 1802-1810.
27. Luo J, Schumacher M, Scherer A, et al. A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics 2012; 10: 278-291.
28. Goodman LA, Kruskal WH., Measures of association for cross classifications. J Am Stat Assoc 1954; 49: 732-764.
29. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168-1179.
30. Mengel M, Chang J, Kayser D, et al. The molecular phenotype of six-week protocol biopsies from human renal allografts: Reflections of prior injury but not future course. Am J Transplant 2011; 11: 708-718.
31. Yamanaka K, Oka K, Nakazawa S, et al. Immunohistochemical features of BK virus nephropathy in renal transplant recipients. Clin Transplant 2012; 26 (Suppl. 24): 20-24.
32. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: Impact on chronic rejection. Transplant 1993; 55: 993-995.
33. Sellares J, De Freitas D, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and non-adherence. Am J Transplant 2012; 12: 388-399.
34. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: A randomized study. Am J Transplant 2007; 7: 2538-2545.
35. Mirnezami R, Nicholson J, Darzi A., Preparing for precision medicine. N Engl J Med 2012; 366: 489-491.
36. Prat A, Parker JS, Fan C, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 2012; 23: 2866-2873.
37. Yang M, Rajan S, Issa AM., Cost effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model. Cancer 2012; 118: 6298-6299.
38. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192.
39. Cardoso F, Van't VL, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ., Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 2008; 26: 729-735.
40. Halloran BP, Chang J, Fedorak RN, Halloran PF., The signals in human T cell mediated rejection are found in refractory ulcerative colitis and correlate with response to infliximab therapy. Gastroenterology 2012; 142: S-657.
41. Opitz D, Maclin R., Popular ensemble methods: An empirical study. J Artif Intell Res 1999; 11: 169-198.